Oslo

• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refract … Ended recruitment
  2023-505212-38-00 3 2022-11-16 Relapsed/Refractory Multiple Myeloma
• SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM Ended recruitment
  2023-508869-32-00 5 2022-11-10 Cancer - Plasma cell myeloma recurrent
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organ … Ended recruitment
  2022-500027-76-00 4 2022-10-05 Colorectal cancer
• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• Daratumumab in ME/CFS Ended recruitment
  2024-512500-19-00 4 2022-04-29 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients Ended recruitment
  2023-506486-60-01 5 2022-04-26 Heart transplant
• NOR-CACTUS Ended recruitment
  2024-511223-34-00 6 2022-04-08 Carpal Tunnel Syndrome
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten … Ended recruitment
  2023-505514-15-00 5 2022-01-11 Small-cell lung cancer, extensive stage
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy … Ended recruitment
  2024-511407-42-00 4 2022-01-10 Advanced Systemic Mastocytosis
• This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2 … Ended recruitment
  2024-513624-42-00 5 2021-12-16 Tenosynovial Giant Cell Tumor
• Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended recruitment
  2023-509864-96-00 4 2021-12-07 Mantle Cell Lymphoma (MCL)
• Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosis Ended recruitment
  2023-510211-20-00 5 2021-12-07 Aortic stenosis
• Zoledronate Early to Hip Fractures Patients – safe and effective? A Randomized controlled double-blinded treatment strategy trial on Zoledro … Ended recruitment
  2023-510198-32-00 6 2021-12-01 Hip fracture
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended recruitment
  2023-508838-33-00 5 2021-10-06 Chronic Myeloid Leukemia
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len … Ended recruitment
  2023-505850-16-00 5 2021-08-05 Multiple Myeloma
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap … Ended recruitment
  2023-506311-18-00 1 2021-06-29 Advanced or metastatic solid tumors with KRAS G12C mutation

Showing 337–360 of 508 trials